Titlebook: Small Molecules in Hematology; Uwe M. Martens Book 2018Latest edition Springer International Publishing AG, part of Springer Nature 2018 S

Compass

Imatinib Mesylate,y well tolerated with a low incidence of severe side effects. The most common adverse events include mild to moderate edema, muscle cramps, diarrhea, nausea, skin rashes, and myelosuppression. Several mechanisms of resistance have been identified. Clonal evolution, amplification, or overexpression o

Exposition

谦卑

Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor,sion of the existing label. In comparison with the other approved TKIs, bosutinib harbors a distinct side effect profile with only very few cardiovascular and thromboembolic events and minimal long-term safety issues with most adverse events happening during the first months of treatment. On the oth

投票

礼节

有花

爱得痛了

Pomalidomide,easome inhibitors (PI: bortezomib, carfilzomib) or antibodies, like elotuzumab or daratumumab. Pomalidomide has also been assessed in AL amyloidosis, MPNs (myelofibrosis [MF]), Waldenstrom’s macroglobulinemia, solid tumors (sarcoma, lung cancer), or HIV, and—for AL amyloidosis and MF—has already bee

讥讽

progestogen

Venetoclax: Targeting BCL2 in Hematological Cancers,stic reduction of the tumor bulk within a few hours after administration. Venetoclax was approved by the FDA and EMA in 2016 for patients with previously treated CLL with del(17p13) and patients failing B cell receptor signaling inhibitors (EMA only), on the basis of a single-arm phase II trial demo

小口啜饮

Carfilzomib,oing studies confirmed a tolerable safety profile of CFZ, a significantly lower incidence of neuropathy compared to bortezomib (BTZ) and a slightly higher incidence of cardiotoxicity, which is closely observed and precautions taken to avoid them as best as possible. In July 2012, the US Food and Dru